))
#050 $SVRA’s Inhaled Hype Hits a Wall
Manage episode 516989010 series 3678700
Content provided by SueWallSt. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by SueWallSt or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
When $SVRA Savara Inc. filed its long-awaited FDA application, investors cheered—until the FDA refused to even review it. In this episode, we dive into the unfolding securities class action accusing Savara of misleading shareholders about its incomplete drug submission. Biotech investors, pharma followers, and Wall Street skeptics this one's for you. Expect sharp breakdowns, timely analysis, and a dose of biotech drama.
Visit ZLK.com for more info.
Add our WhatsApp Channel.
We’re not lawyers or accountants, so don’t take this as legal or financial advice.
54 episodes
Share
